Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Picard Medical (NYSE American: PMI) will implement a 1-for-50 reverse stock split of its issued and outstanding common stock to support continued compliance with NYSE American listing standards. The board approved the split after stockholders authorized a reverse split range of 1-for-15 to 1-for-50 on July 17, 2026.
The reverse split is expected to become effective at 5:00 p.m. ET on July 31, 2026, with PMI shares trading on a split-adjusted basis starting August 3, 2026 under the same ticker and a new CUSIP 71953R 207. Outstanding shares and related equity instruments will be proportionately adjusted, with fractional shares rounded up to the nearest whole share.
Picard Medical (NYSE American: PMI), parent of SynCardia, announced publication of an independent commentary in peer-reviewed journal Artificial Organs on its next-generation Emperor total artificial heart platform, which integrates the Emperor Drive with the SynCardia Total Artificial Heart.
The article reviews total artificial heart history and recent preclinical large-animal implants of the “Emperor TAH.” According to Picard Medical, three acute implants were completed successfully, delivering stable full circulatory support with physiologic autoregulation and no device-related intraoperative failures. The commentary highlights the platform’s independent dual-motor design for separate systemic and pulmonary control and its potential to more closely replicate cardiac function without an external pneumatic driver. It also notes SynCardia’s two decades of clinical experience and that its Total Artificial Heart is the only commercially available device of this type approved in the U.S. and Canada. The publication states the piece is a news update and not an endorsement.
Picard Medical (NYSE American: PMI), parent of SynCardia, released a pre-recorded stockholder presentation ahead of its virtual 2026 Annual Meeting on July 17, 2026. The presentation reviews recent business performance, including an 85% year-over-year revenue increase for the first three months of 2026, driven by a 116% rise in U.S. revenue, and a gross margin of 24% versus -4% in 2025.
Picard Medical outlines manufacturing optimization efforts and development of its next-generation Emperor platform, which replaces the external pneumatic driver with an electromechanical actuation system and targets a fully implantable total artificial heart. Milestones include pursuit of FDA Breakthrough Device designation, continued preclinical studies, a planned IDE submission in 2028, and intended clinical study activities in 2029.
The presentation also summarizes proposals for stockholder vote: election of directors, amendments to the capital structure, auditor ratification, and advisory votes on executive compensation. Stockholders of record may vote online, by phone, or during the virtual meeting.
Picard Medical (NYSE American: PMI), parent of SynCardia, released a pre-recorded presentation ahead of its July 17, 2026 annual stockholder meeting.
The presentation reviews Q1 revenue up 85% year-over-year, U.S. revenue up 116%, gross margin at 28%, manufacturing optimization, Emperor platform development milestones, and key voting proposals, including director elections and capital structure amendments.
Picard Medical (NYSE American: PMI), parent of SynCardia Systems, announced a leadership transition. Patrick NJ Schnegelsberg stepped down as CEO and director effective June 18, 2026, with no disagreement cited regarding company operations or policies.
The Board appointed Executive Chairman Richard Fang, Ph.D. as Interim CEO while it searches for a permanent chief. Fang will retain his chairman role and brings over 20 years of medical device experience, including founding and expanding Reach Surgical and leading it through a sale.
SynCardia continues as maker of the world’s first total artificial heart approved by both the FDA and Health Canada, with an ongoing mission to support patients with advanced biventricular heart failure and its clinical partners.
Picard Medical (NYSE American: PMI), parent of SynCardia, will present new in vivo data on its next-generation Emperor Total Artificial Heart and new patient outcome research on the SynCardia Total Artificial Heart at the ASAIO 2026 conference in New Orleans, June 18–21, 2026.
Talks cover hemodynamic performance of the fully implantable Emperor platform and a holistic analysis of survival, recovery, transplantability, and quality of life for SynCardia Total Artificial Heart patients.
Picard Medical (NYSE American: PMI), parent of SynCardia, reported successful completion of three acute in vivo animal implants of its next-generation Emperor Total Artificial Heart (TAH) at University of Arizona and Banner University Medical Center.
The latest Emperor TAH iteration features an independent dual motor ventricular system, delivered stable hemodynamic support with physiologic autoregulatory behavior, and showed no device-related intraoperative failures. The fully implantable Emperor TAH remains under development and is not FDA approved.
Picard Medical (NYSE American: PMI), parent of SynCardia Systems, reported 2025 revenue of $4.9 million, up 12.5%, and year-end cash of $11.5 million. Q1 2026 revenue rose 85% to $1.2 million with a 24% gross margin, alongside significant debt reduction and balance-sheet simplification efforts.
The SynCardia Total Artificial Heart has surpassed 2,100 implants in 27 countries, and development continues on the fully implantable Emperor TAH. The company is addressing a going-concern qualification and NYSE American stockholders’ equity notices while pursuing a roadmap toward profitability.
Picard Medical (NYSE American: PMI) reported Q1 2026 revenue of $1.2 million, up 85% year over year, driven by greater SynCardia Total Artificial Heart utilization and Freedom Driver rentals. Gross profit turned positive at $0.3 million with 24% margin, while net loss reached $7.6 million.
The company repaid or settled over $10 million of debt, cut its Senior Secured Note balance to about $1.3 million, raised $5.0 million in a May 2026 offering, and simplified its warrant structure. Picard Medical received NYSE American deficiency notices tied to stockholders’ equity and is preparing a compliance plan.
Picard Medical (NYSE American: PMI) priced a "reasonable best efforts" offering to raise approximately $5.0 million through the sale of 16,666,667 common shares (or equivalents) plus Series A and B common warrants at a combined price of $0.30 per share and accompanying warrants.
The Series A and B warrants have a $0.35 exercise price; Series A expires in five years, Series B in 24 months. The company will use net proceeds for working capital and to repay certain senior secured note and loan redemptions. Closing expected on or about May 6, 2026.